Jeffrey Wolf, MD | Authors

Jeffrey Wolf, MD, on the Lack of MRD Results at ASH and the Future of Myeloma Trials

January 05, 2021

Jeffrey Wolf, MD, explained how studies presented at the recent 2020 ASH Annual Meeting & Exposition did not report what percentage of patients achieved minimal residual disease negativity with therapy for multiple myeloma, and that the future of phase 3 trials should focus on this status in patients.